BNBX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: February 25, 2026
Report Source: 2026 1st Quarter Report
BNB Plus Corp. Stock Analysis BNBX
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. The company is headquartered in Stony Brook, New York and currently employs 26 full-time employees. The company went IPO on 2001-08-24. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
Read More BNB Plus Corp (BNBX) Chart
Key Statistics of BNB Plus Corp (BNBX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.48Volume
53.01KP/E Ratio (TTM)
-52 Week Range
Market Cap
2.83MAvg. Volume
1.77MDividend Yield
-Financial Metrics & Statements of BNB Plus Corp (BNBX)
FAQ's for BNB Plus Corp (BNBX)
- According to Musaffa’s Shariah screening methodology, BNB Plus Corp (BNBX) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.